| Advantages | These organoids are valuable for studying peritoneal cancer progression, tumor biology, and chemoresistance. They serve as an ideal platform for disease modeling, drug testing, and targeted therapy development, providing insights into the peritoneal tumor microenvironment and enabling more accurate prediction of specific therapeutic responses. |
| Species | Human |
| Product Type | Tissue-derived Organoid |
| Growth Properties | Embedded 3D Culture |
| Growth Conditions | Cultured at 37°C under 95% air and 5% CO2. |
| Quality Control | Negative for mycoplasma, bacteria, yeast, and fungi. |
| Tissue | Peritoneum |
| Disease | Cancer |
| Format | Frozen |
| Organoid Characterization | They retain the molecular characteristics and tumor heterogeneity of the original cancer, including features such as epithelial-to-mesenchymal transition (EMT) and tumor-stroma interactions. |
| Applications | This organoid is well-suited for translational cancer research, including studies of peritoneal tumor progression, drug resistance, and personalized treatment response. It enables preclinical screening of cytotoxic agents and targeted therapies, including those used in intraperitoneal chemotherapy. Researchers can use this model to investigate tumor-stroma interactions, explore immunotherapy combinations, and validate biomarkers associated with metastasis and recurrence. Human peritoneal cancer organoids are particularly valuable for modeling patient-specific therapeutic outcomes, supporting the development of precision oncology strategies for peritoneal surface malignancies. |
| Storage | Liquid Nitrogen |
| Shipping Information | Dry Ice |
For preclinical research and development use only; not intended for therapeutic or other applications.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.